aby-035
mAbexperimentalBi-specific
Clinical trial activity
10 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02690142)
Timeline
Indications
Mechanism of action
- Interleukin-17 receptor AINHIBITOR
IL17RA inhibitor
- Interleukin 17AINHIBITOR
IL17A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297686 ↗
Also known as
- aby-035
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05905783 | Phase 3 | Jun 22, 2023 | ACELYRIN Inc. |
| NCT05623345 | Phase 2/Phase 3 (Phase 3) | Nov 21, 2022 | ACELYRIN Inc. |
| NCT05384249 | Phase 2 | Aug 23, 2022 | ACELYRIN Inc. |
| NCT05355805 | Phase 2 | May 5, 2022 | ACELYRIN Inc. |
| NCT04706741 | Phase 2 | Oct 31, 2021 | Affibody |
| NCT04795141 | Phase 2 | Apr 26, 2021 | Affibody, Inmagene Biopharmaceuticals |
| NCT04713072 | Phase 2 | Aug 4, 2020 | Affibody |
| NCT03580278 | Phase 1 | Jul 31, 2018 | Affibody |
| NCT03591887 | Phase 2 | Mar 7, 2018 | Affibody, Klinik für Dermatologie, Venerologie und Allergologie, TFS Trial Form Support |
| NCT02690142 | Phase 1 | Feb 1, 2016 | Affibody, Covance |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affibody | For profit | 6 | 5 | 2 | 2016 |
| ACELYRIN Inc. | For profit | 4 | 4 | 2 | 2022 |
| Covance | For profit | 1 | 0 | 1 | 2016 |
| Inmagene Biopharmaceuticals | For profit | 1 | 1 | 1 | 2021 |
| Klinik für Dermatologie, Venerologie und Allergologie | Academic/Hospital | 1 | 0 | 1 | 2018 |
| TFS Trial Form Support | For profit | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1